NEU 1.54% $19.86 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-164

  1. 727 Posts.
    lightbulb Created with Sketch. 167
    Hi hottod

    as a fellow opt holder, although a little later than you, I have been struggling to get my head around the size of each trial arm. I can't see how the statistical robustness of the data would improve greatly from a 100 patient cohort to the 1000 per arm.

    crazy numbers. They were asking for trouble cost wise.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.